TITLE

Medicare study: Bevacizumab, ranibizumab no riskier than other AMD therapies

AUTHOR(S)
Preston, Courtney
PUB. DATE
July 2011
SOURCE
Primary Care Optometry News;Jul2011, Vol. 16 Issue 7, p17
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses results of a retrospective cohort study which showed that bevacizumab and ranibizumab, when compared with pegaptanib use or photodynamic therapy, did not increase the risk level of myocardial infarction and mortality for patients with age-related macular degeneration (AMD).
ACCESSION #
65033428

 

Related Articles

  • YaÅŸa BaÄŸlı Maküla Dejenerasyonunda Fotodinamik Tedavi ile Fotodinamik Tedavi ve Ä°ntravitreal Ranibizumab Kombine Tedavisinin Uzun Dönem Sonuçları. Acar, Damla ergintürk; Ünlü, Nurten; Haziloran, Dicle; Üney, Güner; Acar, Mehmet Akif // Retina-Vitreus/Journal of Retina-Vitreous;Dec2011, Vol. 19 Issue 4, p250 

    Purpose: To compare the effectiveness of photodynamic therapy (PDT) monotheraphy with PDT combined with intravitreal (IV) ranibizumab in age-related macular degeneration (AMD). Material and Methods: Fifty six eyes of 55 patients with the diagnosis of choroidal neovascularization (CNV) secondary...

  • Dissecting the Promise of PDT. McDermott, Gilliam K. // Review of Ophthalmology;Aug2000, Vol. 7 Issue 8, p73 

    Investigates photodynamic therapy (PDT) in the treatment of age-related macular degeneration. Advantages of PDT over standard laser treatment involving the photocoagulation of the choroidal neovascular membranes of the retina; Photosensitizing agents used in PDT; Safety of the procedure;...

  • A new health technology: where is the consensus on a clinically worthwhile benefit? Foot, B.; Foy, R.; Chakravarthy, U.; Wormald, R. // Eye;Jul2002, Vol. 16 Issue 4, p469 

    Aim: New therapies are often introduced into the NHS prior to full evaluation, leading to inequities in provision. Uncertainty exists regarding the value of photodynamic therapy in the treatment of neovascular age-related macular degeneration. We ascertained the availability of this...

  • Ranibizumab looks "highly cost-effective" in wet AMD.  // PharmacoEconomics & Outcomes News;6/11/2011, Issue 630, p12 

    The article discusses research on the cost-effectiveness of the use of ranibizumab in wet macular degeneration (AMD), presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.

  • Bevacizumab for the treatment of neovascular age related macular degeneration. Chakravarthy, Usha // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/26/2010, Vol. 340 Issue 7761, p1370 

    The author analyzes the effectiveness of bevacizumab in treating neovascular age related macular degeneration. He notes that ophthalmologists administered the drug intravenously at first but soon changed it to intraocular delivery due to potential systemic adverse events of intravenous...

  • Age-related macular degeneration: a case study. Kerr, Elizabeth // British Journal of Nursing;6/10/2010, Vol. 19 Issue 11, p693 

    This case study concerns a patient undergoing treatment for age-related macular degeneration (ARMD) by intravitreal injections of ranibizumab (Lucentis). ARMD is the leading causing of blindness in people over 50 in the western world, and seriously affects individuals' ability to carry out basic...

  • Ranibizumab cost effective for AMD in Austria.  // PharmacoEconomics & Outcomes News;11/29/2008, Issue 567, p3 

    The article focuses on a study on the cost effectiveness of ranibizumab for the treatment age-related macular degeneration in Austria, discussed at the 11th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 2008. The study revealed...

  • Bevacizumab.  // Reactions Weekly;4/28/2007, Issue 1149, p9 

    The article presents two case studies of acute endophthalmitis that developed after receiving intravitreal bevacizumab injections for the treatment of macular degeneration. It references a study by F. B. Aggio et al published in the March 2007 issue of the "Eye." Both patients developed corneal...

  • Photodynamic therapy trials are continuing for AMD. GUTTMAN, CHERYL; Schachat, Andrew P.; Slakter, Jason // Ophthalmology Times;10/15/98, Vol. 23 Issue 20, p9 

    Evaluates the efficacy and safety of photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) based on multicenter trials. Temporary treatment effect of PDT; Recurrence of CNV after standard photocoagulation; Method...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics